Furter investigations on the interaction between alpha-adrenoceptor antagonists and the central hypotensive effect of clonidine in rats, rabbits and dogs

Imidazoline receptors: from discovery to antihypertensive therapy (facts and doubts)

The hypothesis and indirect evidence of imidazoline receptors has been promoted since some 15 years ago and it gave a substantial impetus for research in this field, resulting in a better understanding of neuronal and cardiovascular regulatory processes. The nomenclature of the imidazoline receptors has been accepted by international forums but no direct proof for the existence of these receptors has been published. Authors summarise the most important available data, including facts and doubts as far as the discovery, characterisation, and function of imidazoline receptors and their subtypes, the differences between imidazoline receptors and alpha-2 adrenoceptors, and also on their participation in regulatory processes.

Pharmacological characterization and regional distribution of alpha-noradrenergic binding sites of rat spinal cord

In order better to interpret their physiological role in rat spinal cord, we characterized binding sites of [3H]WB-4101 and [3H]p-aminoclonidine ( [3H] PAC), and determined their regional distribution. These binding sites have characteristics required for, respectively, alpha 1 and alpha 2 receptors of norepinephrine. Binding to these sites is saturable, with Kd values of 0.38 nM and 35 nM for high and low affinity binding sites respectively of [3H]WB-4101; and 1.7 nM, for a single binding site of [3H]PAC. For whole cord, Bmax values are 52 and 320 (high and low affinity sites respectively); and 21 fmol/mg protein. Catecholamines compete stereoselectively for these sites, while selected noradrenergic agents compete with an order of potency corresponding to their relative activity at the alpha 1 and alpha 2 receptors. We conclude that spinal alpha 1 and alpha 2 binding sites have the same pharmacologic properties as corresponding peripheral sites. The alpha 2 and, to a lesser degree, the alpha 1 binding sites vary in concentration with region. Our results support the contention that alpha 2 binding sites subserve neuronal function in the spinal cord.

The alpha 1- and alpha 2-adrenoceptor involvement in the central cardiovascular action of clonidine in the conscious renal hypertensive cat

An attempt has been made to characterise the alpha-adrenoceptor subtype (alpha 1 or alpha 2) mediating the hypotensive and bradycardic action of clonidine in conscious renal hypertensive cats. The relatively selective alpha 2-adrenoceptor agonists clonidine, UK-14,304, guanfacine and lofexidine caused significant hypotension and bradycardia when given intracerebroventricularly (i.c.v.). This suggests that alpha 2-adrenoceptors can mediate hypotension and bradycardia. However, both alpha 1- and alpha 2-adrenoceptor antagonists, prazosin, UK-33,274, corynanthine, yohimbine, rauwolscine and RS21361 blocked the hypotensive effect of clonidine. These results suggest an alpha 1-adrenoceptor may also mediate the central hypotensive action of clonidine, or possibly that the central alpha-adrenoceptors in which clonidine acts, may show pharmacological differences to peripheral alpha 1- and alpha 2-subtypes.

Cardiovascular effects of clonidine in an avian species, Larus argentatus

Blood pressure and heart rate were recorded in the sea gull, Larus argentatus, under light pentibarbitone anaesthesia. Clonidine 10(-7) and 10(-8) mol . kg-1 (27 and 2.7 microgram . kg-1) i.v. produced a biphasic effect on blood pressure, a brief initial increase being followed by a prolonged hypotensive response. There was an immediate reduction in heart rate rate which persisted throughout the hypotensive phase. After spinal transection at the level of C4, clonidine administration elicited hypertension and bradycardia. Bilateral vagotomy abolished the effect of clonidine on heart rate but did not alter the blood pressure response. Vagotomy in combination with spinal transection abolished the effect of clonidine on heart rate but the hypertensive response was accentuated. Yohimbine 10(-7) or 10(-6) mol . kg-1 (0.039 or 0.39 mg . kg-1) given 5 min after clonidine 10(-7) mol.kg-1 (27 microgram . kg-1) effectively antagonized the cardiovascular effects of clonidine, while prazosin 10(-7) or 10(-6) mol . kg (0.042 or 0.42 mg . kg-1) had no such effect. We conclude that clonidine acts in the central nervous system of the sea gull to produce a lowering of blood pressure and heart rate. These effects are mediated by central inhibition of sympathetic activity and, in the case of the heart rate, mostly by central activation of vagal activity to the heart. This central action of clonidine involves activation of alpha-adrenoceptors which are blocked by yohimbine but not by prazosin and therefore may belong to the alpha 2 subtype.

Pharmacological characteristics of spinal alpha-adrenoreceptors in rats

1 Spinal alpha-adrenoreceptors involved in cardiovascular control have been investigated using selective alpha-adrenoreceptor agonists and antagonists in urethane-anaesthetized rats. 2 Intrathecal injections of clonidine, alpha-methylnoradrenaline, guanfacine and M7 at the C7-T1 level reduced blood pressure and heart rate. In contrast, phenylephrine, 5-hydroxytryptamine and procaine had little or no effect. These results suggest the involvement of spinal alpha 2-adrenoreceptors. 3 The fall in blood pressure produced by clonidine appeared to be attributable to a reduction in heart rate and stroke volume. Lower body vascular resistance was unchanged. 4 The clonidine-induced bradycardia was antagonised by prazosin, WB4101, piperoxan or yohimbine. Their relative potencies suggest that alpha 1-rather then alpha 2-adrenoreceptors mediate this response. 5 piperoxan and yohimbine clearly prevented the clonidine-induced fall in blood pressure; prazosin and WB4101 also appeared to antagonise clonidine but these results were complicated by the fact that these antagonists themselves reduced blood pressure. 6 It was difficult to interpret these results simply in terms of alpha 1- or alpha 2-adrenoreceptors. Thus spinal alpha-adrenoreceptors may be different from peripheral alpha 1- or alpha 2-adrenoreceptors.